A Novel, High-efficiency Cellular Model of Fibrillar Alpha-synuclein Inclusions and the Examination of Mutations That Inhibit Amyloid Formation

Overview

Journal J Neurochem

Specialties Chemistry
Neurology

Date 2010 Feb 6

PMID 20132485

Citations 48

Authors

Elisa A Waxman

Benoit I Giasson

Affiliations

Soon will be listed here.

Abstract

Intracytoplasmic alpha-synuclein (alpha-syn) amyloidogenic inclusions are a major pathological feature of Parkinson's disease, dementia with Lewy body disease and multiple systems atrophy. The mechanisms involved in the formation and inhibition of these aggregates are areas of intense investigation. The present study characterizes a novel cellular model for the study of alpha-syn aggregation, incorporating nucleation-dependent aggregation and a new function for calcium phosphate precipitation. Cultured cells were readily induced to develop large, cytoplasmic alpha-syn filamentous aggregates that were hyperphosphorylated, often ubiquitinated and thioflavin positive. These cellular aggregates formed in the majority of transfected cells and recruited approximately half of endogenously expressed alpha-syn. Using this system, we examined single-point mutations that inhibit alpha-syn amyloid formation in vitro. Three mutations (V66P, T72P and T75P) significantly hindered alpha-syn aggregation in this cell model. The T75P mutant, which could abrogate amyloid formation of wild-type alpha-syn in vitro, did not prevent wild-type alpha-syn cellular aggregates. These studies suggest that the propensity of alpha-syn to form cellular aggregates may be more pronounced than in isolated in vitro studies. This novel high-efficiency cellular model of alpha-syn aggregation is a valuable system that may be used to further understand alpha-syn aggregation and allow for the generation of future therapeutics.

Citing Articles

Novel Monoclonal Antibody Specific toward Amyloid-β Binds to a Unique Epitope within the N-Terminal Region.

Paterno G, Moore B, Bell B, Gorion K, Ran Y, Prokop S Antibodies (Basel). 2024; 13(3).

PMID: 39189239 PMC: 11348109. DOI: 10.3390/antib13030068.

O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology.

Balana A, Mahul-Mellier A, Nguyen B, Horvath M, Javed A, Hard E Nat Chem Biol. 2024; 20(5):646-655.

PMID: 38347213 PMC: 11062923. DOI: 10.1038/s41589-024-01551-2.

Cellular processing of α-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114.

Quintin S, Lloyd G, Paterno G, Xia Y, Sorrentino Z, Bell B J Biol Chem. 2023; 299(7):104912.

PMID: 37307916 PMC: 10404685. DOI: 10.1016/j.jbc.2023.104912.

Effects of Mutations and Post-Translational Modifications on α-Synuclein In Vitro Aggregation.

Pancoe S, Wang Y, Shimogawa M, Perez R, Giannakoulias S, Petersson E J Mol Biol. 2022; 434(23):167859.

PMID: 36270580 PMC: 9922159. DOI: 10.1016/j.jmb.2022.167859.

Regulates Transmission of α-Synuclein-Seeded Pathology in Mice.

De La Cruz E, Vo Q, Moon K, McFarland K, Weinrich M, Williams T Int J Mol Sci. 2022; 23(15).

PMID: 35897751 PMC: 9332117. DOI: 10.3390/ijms23158175.

References

Liu J, Zhang J, Shi M, Quinn T, Bradner J, Beyer R . Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 2009; 29(5):1480-5. PMC: 3241981. DOI: 10.1523/JNEUROSCI.6202-08.2009. View

Zibaee S, Jakes R, Fraser G, Serpell L, Crowther R, Goedert M . Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. J Mol Biol. 2007; 374(2):454-64. DOI: 10.1016/j.jmb.2007.09.039. View

Garcia-Mata R, Bebok Z, Sorscher E, Sztul E . Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol. 1999; 146(6):1239-54. PMC: 2156127. DOI: 10.1083/jcb.146.6.1239. View

Hashimoto M, Hsu L, Sisk A, Xia Y, Takeda A, Sundsmo M . Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 1998; 799(2):301-6. DOI: 10.1016/s0006-8993(98)00514-9. View

Lee H, Suk J, Bae E, Lee J, Paik S, Lee S . Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008; 40(9):1835-49. DOI: 10.1016/j.biocel.2008.01.017. View

Lee H, Shin S, Choi C, Han Lee Y, Lee S . Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 2001; 277(7):5411-7. DOI: 10.1074/jbc.M105326200. View

Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H . Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell. 2001; 12(5):1393-407. PMC: 34592. DOI: 10.1091/mbc.12.5.1393. View

Kordower J, Chu Y, Hauser R, Freeman T, Olanow C . Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008; 14(5):504-6. DOI: 10.1038/nm1747. View

Lee V, Trojanowski J . Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006; 52(1):33-8. DOI: 10.1016/j.neuron.2006.09.026. View

10.

Zhuang Z, Kung M, Hou C, Skovronsky D, Gur T, Plossl K . Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem. 2001; 44(12):1905-14. DOI: 10.1021/jm010045q. View

11.

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

12.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

13.

Conway K, Harper J, Lansbury Jr P . Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 2000; 39(10):2552-63. DOI: 10.1021/bi991447r. View

14.

von Bohlen Und Halbach O . Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 2004; 318(1):163-74. DOI: 10.1007/s00441-004-0921-7. View

15.

Glenner G . Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980; 302(23):1283-92. DOI: 10.1056/NEJM198006053022305. View

16.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

17.

Tsuchiya K, Tajima H, Kuwae T, Takeshima T, Nakano T, Tanaka M . Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions. Eur J Neurosci. 2005; 21(2):317-26. DOI: 10.1111/j.1460-9568.2005.03870.x. View

18.

Waxman E, Mazzulli J, Giasson B . Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry. 2009; 48(40):9427-36. PMC: 2758333. DOI: 10.1021/bi900539p. View

19.

Waxman E, Covy J, Bukh I, Li X, Dawson T, Giasson B . Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J Neuropathol Exp Neurol. 2009; 68(7):785-96. PMC: 2722758. DOI: 10.1097/NEN.0b013e3181aaf4fd. View

20.

Zhou W, Freed C . Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem. 2003; 279(11):10128-35. DOI: 10.1074/jbc.M307563200. View